Prosecution Insights
Prosecution Insights
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (20%) |
| No statute on record | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.2% |
| SABOUR, GHAZAL | 1 | 28.1% | +28.6% |
| FAUST, AMBER KATHLEEN | 1 | 62.3% | +50.3% |
| STUART, CAREY ALEXANDER MC | 1 | 61.3% | +38.3% |
| SANG, HONG | 1 | 54.7% | +61.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17495571 | METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS | SABOUR, GHAZAL | 43d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17481781 | CORONAVIRUS VACCINES AND METHODS OF USE | STUART, CAREY ALEXANDER MC | 128d overdue |
| 17253922 | NEOANTIGENS AND USES THEREOF | SANG, HONG | 73d overdue |
| 17495571 | METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS | SABOUR, GHAZAL | 43d overdue |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | FAUST, AMBER KATHLEEN | 2d overdue |
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | ROONEY, NORA MAUREEN | 34d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1686 | 1 |
| 1643 | 1 |
| 1671 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18334820 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | ROONEY, NORA MAUREEN | 1641 | §102 | Non-Final OA | 34d | Pending | Jun 14, 2023 |
| 17495571 | METHOD AND SYSTEMS FOR PREDICTION OF HLA CLASS II-SPECIFIC EPITOPES AND CHARACTERIZATION OF CD4+ T CELLS | SABOUR, GHAZAL | 1686 | Other | Non-Final OA | 43d overdue | Pending | Oct 06, 2021 |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | FAUST, AMBER KATHLEEN | 1643 | Other | Final Rejection | 2d overdue | Pending | Sep 28, 2021 |
| 17481781 | CORONAVIRUS VACCINES AND METHODS OF USE | STUART, CAREY ALEXANDER MC | 1671 | Other | Final Rejection | 128d overdue | Pending | Sep 22, 2021 |
| 17253922 | NEOANTIGENS AND USES THEREOF | SANG, HONG | 1646 | Other | Non-Final OA | 73d overdue | Pending | Dec 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial